MrM - I agree that in a way the FDA let the cat out of the bag regarding whether to severely restrict lower risk patients (primary prevention or lower TGs) as they raised questions about in their adcom briefing document. If they really wanted to do that, they'd have had a voting question about whether the trial proved efficacy for them, and would have strongly made the "no" case at the hearing and phrased the question to all but force a no vote. They didn't do that or anything close to it.
IMO the question is whether the approved market is huge or extremely huge IMO.
News 
Market Data 
Discover 
AI
